- Browse by Author
Browsing by Author "Iuliano, Rodolfo"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item 60kDa Lysophospholipase, a New Sgk1 Molecular Partner Involved in the Regulation of ENaC(2010) Menniti, Miranda; Iuliano, Rodolfo; Föller, Michael; Sopjani, Mentor; Alesutan, Ioana; Mariggiò, Stefania; Nofziger, Charity; Perri, Angela M.; Amato, Rosario; Blazer-Yost, Bonnie; Corda, Daniela; Lang, Florian; Perrotti, NicolaThe serum- and glucocorticoid-regulated kinase (Sgk1) is essential for hormonal regulation of ENaC-mediated sodium transport and is involved in the transduction of growth-factor-dependent cell survival and proliferation. The identification of molecular partners for Sgk1 is crucial for the understanding of its mechanisms of action. We performed a yeast two-hybrid screening based on a human kidney cDNA library to identify molecular partners of Sgk1. As a result the screening revealed a specific interaction between Sgk1 and a 60 kDa Lysophospholipase (LysoLP). LysoLP is a poorly characterized enzyme that, based on sequence analysis, might possess lysophospholipase and asparaginase activities. We demonstrate that LysoLP has indeed a lysophospholipase activity and affects metabolic functions related to cell proliferation and regulation of membrane channels. Moreover we demonstrate in the Xenopus oocyte expression system that LysoLP downregulates basal and Sgk1-dependent ENaC activity. In conclusion LysoLP may represent a new player in the regulation of ENaC and Sgk1-dependent signaling.Item Kinase Inhibitors in Genetic Diseases(MDPI, 2023-03-09) D’Antona, Lucia; Amato, Rosario; Brescia, Carolina; Rocca, Valentina; Colao, Emma; Iuliano, Rodolfo; Blazer-Yost, Bonnie L.; Perrotti, Nicola; Biology, School of ScienceOver the years, several studies have shown that kinase-regulated signaling pathways are involved in the development of rare genetic diseases. The study of the mechanisms underlying the onset of these diseases has opened a possible way for the development of targeted therapies using particular kinase inhibitors. Some of these are currently used to treat other diseases, such as cancer. This review aims to describe the possibilities of using kinase inhibitors in genetic pathologies such as tuberous sclerosis, RASopathies, and ciliopathies, describing the various pathways involved and the possible targets already identified or currently under study.